MedTrace Logo

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01613599 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-07-26

Study results available
· View outcomes & findings →

Summary

This prospective observational study will evaluate the long-term safety of MabThera/Rituxan (rituximab) in participants with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Data will be collected for a maximum of 4 years from participants initiated on MabThera/Rituxan therapy by their physician according to prescribing information.

Conditions

  • Granulomatosis With Polyangiitis
  • Microscopic Polyangiitis

Interventions

DRUG

Rituximab

Participants received rituximab at the discretion of their treating physicians.

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Genentech, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-20
Primary Completion
2015-07-13
Completion
2017-04-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01613599 on ClinicalTrials.gov